Cargando…
MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
Larynx cancer organ preservation treatments with chemo and radiotherapy have substantially improved laryngoesophageal dysfunction-free survival. However, both of them lead to a high incidence of acute and chronic toxicities and a significant number of patients relapse. To date, there is no evidence...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494962/ https://www.ncbi.nlm.nih.gov/pubmed/25788275 |
_version_ | 1782380179106037760 |
---|---|
author | de Miguel-Luken, María-José Chaves-Conde, Manuel de Miguel-Luken, Verónica Muñoz-Galván, Sandra López-Guerra, José Luis Mateos, Juan C. Pachón, Jerónimo Chinchón, David Suarez, Vladimir Carnero, Amancio |
author_facet | de Miguel-Luken, María-José Chaves-Conde, Manuel de Miguel-Luken, Verónica Muñoz-Galván, Sandra López-Guerra, José Luis Mateos, Juan C. Pachón, Jerónimo Chinchón, David Suarez, Vladimir Carnero, Amancio |
author_sort | de Miguel-Luken, María-José |
collection | PubMed |
description | Larynx cancer organ preservation treatments with chemo and radiotherapy have substantially improved laryngoesophageal dysfunction-free survival. However, both of them lead to a high incidence of acute and chronic toxicities and a significant number of patients relapse. To date, there is no evidence available to establish the group of patients that may benefit from preservation approaches and clinical criteria such as primary tumor extension or pretreatment tracheotomy are not validated. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The tumoral behavior induced by MAP17 is associated with reactive oxygen species production in which SGLT1 seems involved. In this study we found that the levels of MAP17 were related to clinical findings and survival in a cohort of 58 patients with larynx cancer. MAP17 expression is associated with overall survival (p<0.001) and laryngoesophageal dysfunction-free survival (p=0.002). Locoregional control in patients with high MAP17 showed better outcomes than those with low MAP17 (p=0.016). Besides, a positive correlation was observed between MAP17 expression and SGLT (p=0.022) and the combination of high levels of MAP17/SGLT also led to an increased overall survival (p=0,028). These findings suggest that MAP17, alone or in combination with SGLT1, may become a novel predictive biomarker for laryngeal carcinoma. |
format | Online Article Text |
id | pubmed-4494962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-44949622015-07-13 MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer de Miguel-Luken, María-José Chaves-Conde, Manuel de Miguel-Luken, Verónica Muñoz-Galván, Sandra López-Guerra, José Luis Mateos, Juan C. Pachón, Jerónimo Chinchón, David Suarez, Vladimir Carnero, Amancio Oncotarget Research Paper Larynx cancer organ preservation treatments with chemo and radiotherapy have substantially improved laryngoesophageal dysfunction-free survival. However, both of them lead to a high incidence of acute and chronic toxicities and a significant number of patients relapse. To date, there is no evidence available to establish the group of patients that may benefit from preservation approaches and clinical criteria such as primary tumor extension or pretreatment tracheotomy are not validated. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The tumoral behavior induced by MAP17 is associated with reactive oxygen species production in which SGLT1 seems involved. In this study we found that the levels of MAP17 were related to clinical findings and survival in a cohort of 58 patients with larynx cancer. MAP17 expression is associated with overall survival (p<0.001) and laryngoesophageal dysfunction-free survival (p=0.002). Locoregional control in patients with high MAP17 showed better outcomes than those with low MAP17 (p=0.016). Besides, a positive correlation was observed between MAP17 expression and SGLT (p=0.022) and the combination of high levels of MAP17/SGLT also led to an increased overall survival (p=0,028). These findings suggest that MAP17, alone or in combination with SGLT1, may become a novel predictive biomarker for laryngeal carcinoma. Impact Journals LLC 2015-02-28 /pmc/articles/PMC4494962/ /pubmed/25788275 Text en Copyright: © 2015 de Miguel-Luken et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper de Miguel-Luken, María-José Chaves-Conde, Manuel de Miguel-Luken, Verónica Muñoz-Galván, Sandra López-Guerra, José Luis Mateos, Juan C. Pachón, Jerónimo Chinchón, David Suarez, Vladimir Carnero, Amancio MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer |
title | MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer |
title_full | MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer |
title_fullStr | MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer |
title_full_unstemmed | MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer |
title_short | MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer |
title_sort | map17 (pdzkip1) as a novel prognostic biomarker for laryngeal cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494962/ https://www.ncbi.nlm.nih.gov/pubmed/25788275 |
work_keys_str_mv | AT demiguellukenmariajose map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer AT chavescondemanuel map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer AT demiguellukenveronica map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer AT munozgalvansandra map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer AT lopezguerrajoseluis map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer AT mateosjuanc map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer AT pachonjeronimo map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer AT chinchondavid map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer AT suarezvladimir map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer AT carneroamancio map17pdzkip1asanovelprognosticbiomarkerforlaryngealcancer |